Thymosin Beta-4: What It Is and What the Research Shows

At a glance:

What is thymosin beta-4?

Thymosin beta-4 is a small, naturally occurring 43-amino acid peptide found in most cells and body fluids, released at sites of injury by platelets and immune cells. It plays a role in cell movement and tissue repair. It is sold through wellness and "research peptide" channels for recovery and healing, and it is not an approved medicine. (A marketed fragment of this peptide, TB-500, is catalogued separately.)

How does it work?

Thymosin beta-4 binds a cell-structure protein called actin and promotes cell migration, the mobilization of stem and progenitor cells, new blood-vessel formation, and reduced inflammation and scarring. This mechanism is well characterized in laboratory and animal models of wound, eye, heart, and nervous-system repair. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. Thymosin beta-4 is not approved by the FDA. In sport, it is prohibited at all times under the growth-factor section of the WADA list. (Note: the full-length peptide was not among the items reviewed at the 2026 FDA compounding advisory meetings; its marketed fragment TB-500 was.)

What does the research show?

The animal and laboratory base is large, but human data are early-stage. According to PubMed, human experience is confined to small or early trials, such as a review of its regenerative properties and a randomized dose-escalation venous-ulcer study assessing safety and tolerability. No pivotal trial has established efficacy for a general recovery or wellness use, so its marketed benefit is unproven in people.

Evidence strength

Low research: There is a strong mechanism and preclinical base, but only small, early human trials, with no efficacy established for the marketed recovery or wellness use. Sources: a review of thymosin beta-4's regenerative properties (Goldstein et al., Expert Opinion on Biological Therapy, 2012, DOI: 10.1517/14712598.2012.634793) and a venous-ulcer study (Guarnera et al., Annals of the New York Academy of Sciences, 2007, DOI: 10.1196/annals.1415.003), indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.